The efficacy of daprodustat in treating anemia in dialysis patients

Recent research indicates that dialysis-dependent patients with anemia exhibited a substantial increase in serum hemoglobin and total iron binding capacity (TIBC), along with a decrease in serum ferritin, following the administration of daprodustat, in a manner that depended on the dosage. This study’s findings were published in The Pan African Medical Journal.

A systemic search of the databases PubMed, Scopus, Web of Science, and Cochrane was conducted. Seven distinct trials were ultimately selected for systematic review, with six of them involving a total of 759 patients included in the network meta-analysis (NMA).

The administration of daprodustat 25-30 mg resulted in the largest change in serum hemoglobin (MD=1.86, 95% confidence interval = [1.20; 2.52]), ferritin (MD= -180.84, 95% confidence interval = [-264.47; -97.20]), and total iron binding capacity (TIBC) (MD=11.03, 95% confidence interval = [3.15; 18.92]) from initial values.

It can be concluded that the administration of daprodustat resulted in a marked elevation in serum hemoglobin and total iron binding capacity (TIBC), and a reduction in serum ferritin among dialysis-dependent individuals with anemia, in a manner that depended on the dosage.